Advertisement
<< Back To Article
Long-Acting Antibody Treatment for Resistant HIV Continues to Show Promise
David Scondras
Ibalizumab is the mab David Ho has been working on for quite awhile. He and another group headed by a Dr. Olsen also developed another mab called Pro140 which has been in a trial at Drexel. It has shown extraordinaty power is probably synergistic with Ibalizumab but most importantly unlike Ibalizumab is not cross resistant to viral strains resistant to Marivaroc and therefore with Ibalizumab might create a 'monoclonal cocktail'. PRO140 reduces viral load 2 logs for 21 days with once subq dose
October 11, 2017 • Cambridge MA